(6/14/10) Novartis Oncology to Honer Monica Warner with Adocacy Award
Novartis Oncology has announced its 2010 Warner Advocacy Award named in honor of Monica Warner, a driving force behind the Carcinoid Cancer Foundation for two decades and an extraordinary advocate for carcinoid and neuroendocrine tumor patients. The award will be presented to “the patient, caregiver, or citizen who most embodies the spirit with which Mrs. Warner assisted patients.” Nominations are now being accepted and all submissions are due by noon on August 1, 2010. Learn more... Download a nomination form (DOC format)...
(1/22/10) What If My Insurance Won’t Pay?
The Carcinoid Cancer Foundation is partnering with Laurie Todd, “The Insurance Warrior,” to bring you the most up-to-date information on how to fight your insurance company if they deny your claim for medication or treatment. Click here to read the first installment...
(12/12/09) 2009 National Carcinoid/NET Patient Conference
New Orleans, Louisiana
September 24-25, 2009
The Carcinoid Cancer Awareness Network (CCAN) in association with Ochsner Medical Center, Kenner held the 2009 National Carcinoid / NET Patient Conference at the Astor Crowne Plaza Hotel in New Orleans in September. The conference was attended by some 500 patients, family members, caregivers, and physicians.
(11/23/09) Carcinoid Cancer Foundation Appoints New CEO
Keith R.P. Warner, President of Highland Water LLC in Denver, Colorado, has been named Chief Executive Officer of the Carcinoid Cancer Foundation (CCF), a national and international nonprofit organization with headquarters in White Plains, New York. The appointment was announced by Richard R.P. Warner, M.D., Medical Director of the Foundation, who said, “I am delighted that CCF’s Board of Directors has selected my son for the position of CEO. The Foundation was founded by my family and patients in the late 1960s to enable me to continue my research on this rare cancer. With Keith Warner’s appointment, the legacy of the Foundation will continue. His background in business and administration makes him the ideal CEO for the fifth decade and beyond of The Carcinoid Cancer Foundation.” Read more...
Nissen, Nicholas N.; Kim, Amanda S.; Yu, Run; Wolin, Edward M.; Friedman, Marc L.; Lo, Simon K.; Wachsman, Ashley M.; Colquhoun, Steven D.
The American Surgeon, Volume 75, Number 10, October 2009, pp. 1025-1029(5)
ABSTRACT: Pancreatic neuroendocrine tumors (pNETs) are an uncommon pancreatic neoplasm. We reviewed the presentation, management, and outcome of patients with pNETs treated at a single center by a multidisciplinary approach between 2004 and 2008. Over this time period, 154 patients with carcinoid and neuroendocrine tumors were treated, which included 46 patients (30% of total) with pNETs. The most common presentations included abdominal pain (20 of 46 [43%]), systemic symptoms such as hypoglycemia (15 of 46 [33%]), and incidental mass (7 of 46 [15%]). Fourteen patients had functional tumors. At the time of diagnosis, 22 patients (48%) presented without metastases and 24 (52%) had metastatic disease. Median follow up for the entire group was 42 months. All patients with nonmetastatic pNET underwent pancreatic resection with 95 per cent postoperative survival. Overall survival in this group at 3 years was 86 per cent and disease-free survival was 81 per cent. In patients presenting with metastatic pNET, multiple treatment modalities were used, including liver resection or ablation (n = 15), hepatic chemoembolization (n = 17), pancreatic resection (n = 12), and systemic treatments (n = 7). Three-year survival was 70 per cent. Pancreatic resection results in greater than 80 per cent 3-year survival in nonmetastatic pNET. In patients presenting with metastatic pNET, excellent survival rates are also achievable using a multidisciplinary multimodal approach.
PMID: 19886158 [Pubmed – as supplied by publisher]
The Lois Merrill Foundation is a nonprofit organization founded in 2007 in honor of Lois Merrill who passed away in 2006 from carcinoid cancer. Lois was a devoted wife, mother and school teacher whose passion for life and sincere desire to help others lives on through The LMF. The mission of The Lois Merrill Foundation is to help people affected by carcinoid cancer through funding research for new treatments, providing financial support for patients and their families, and promoting awareness and education for carcinoid and other rare cancers.
For information about financial resources available to patients, click here: http://www.theloismerrillfoundation.org/wecanhelp.html. Medical assistance grants are based on financial need. Grant requests are reviewed two times a year: on November 1 and May 1.
(11/9/09) November is Carcinoid Cancer Awareness Month in New York
Governor David A. Paterson has proclaimed November 2009 as Carcinoid Cancer Awareness Month in New York State to “ensure that public education and medical services are available to reduce the number of misdiagnoses of Carcinoid patients and to enable early detection and treatment options to enhance quality of life and survival rate of Carcinoid patients, with the hopes of one day finding a cure. . .”
Click on the Proclaimation image to the right for a larger size PDF version...
BACKGROUND: Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow-up are lacking. AIM: To present long-terms results with octreotide LAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome.
METHODS: A total of 108 patients with metastatic midgut neuroendocrine tumours were included in this 8-year study. Clinical evaluation was based on a symptom score. Radiological assessment was based on RECIST (Response Evaluation Criteria In Solid Tumours) criteria.
RESULTS: Of the 108 patients, 24% had a sustained symptomatic response. In the remaining patients, loss of symptomatic response with the initial dose was noted within 3-60 months. In 17% of them, symptoms were controlled by just an increase of octreotide LAR dose, whilst the other patients required additional treatment. Overall, in 45.3% of patients, symptoms were well controlled during the study period with only octreotide LAR, and no additional treatment was required. No significant adverse effects were noted.
CONCLUSIONS: Octreotide LAR treatment provides a sustained symptomatic response in about half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described. PMID: 19573169 [PubMed - in process]
Vinik AI, Silva MP, Woltering G, Go VL, Warner R, Caplin M.
Eastern Virginia Medical School, Strelitz Diabetes Research Center, Norfolk, VA 23510, USA. vinikai@evms.edu
ABSTRACT: In this review, we focus on the use of biochemical markers for the diagnosis of neuroendocrine tumors and exclusion of conditions that masquerade as neuroendocrine tumors. In addition, we outline the use of biochemical markers for follow-up, response to intervention, and determination of prognosis. Previous publications have focused only on markers specific to certain tumor types, but the uniqueness of this chapter is that it presents a new approach ranging from biochemical markers that relate to symptoms to the use of markers that facilitate decision making with regard to optimizing the choices of therapy from the complex arrays of intervention, The sequence of presentation in this chapter is first to provide the usual view, that is, biochemical markers of each tumor type and thereafter the diagnosis of the underlying condition or exclusion thereof and finally the algorithm for their use from the clinical presentation to the suspected diagnosis and the biochemical markers to monitor progression and therapeutic choice. There is also a specific description of the properties of the most important biochemical markers and 2 complications, bone metastasis and carcinoid heart disease, from the biochemical point of view.
PMID: 19855234 [PubMed - in process]
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold, Thomas Gress, and Rudolf Arnold
Journal of Clinical Oncology. 2009 Oct 1;27(28):4656-63.
Conclusion: Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
CCF's 12th Annual Carcinoid NETs Symposium,
Mt Sinai Hospital New York, NY
Sunday April 2009
ON THE CUTTING EDGE
The theme of the lectures were advances in surgical care for Carcinoid and Neuroendocrine tumors. The talk featured presentations by distinguished guest speakers Dr. Philip J. Boudreaux, Surgeon and Professor of Surgery at Louisiana State University Hospital School of Medicine (in Kenner, Louisiana) and Dr. Rodney F. Pommier, Surgeon and Professor of Surgery at Oregon Health Sciences University Cancer Institute (in Portland, Oregon). View Video... View Photo/slide show...
Chromgranin A(CgA) - At A Glance
Why test ? Read more...
MedlinePlus: Carcinoid Tumors updated February 2009
Services and providers for Carcinoid Tumors in the U.S. The primary NIH organization for research on Carcinoid Tumors is the National Cancer Institute. This is an amazinginly comprehensive resource summary of information about carcinoid from major medical institutions. Access their paper...
CCF in the news
"Carcinoid Cancer Foundation Sets Sights on Raising Awareness" Read more...
PRESS RELEASE by Charity Happenings.org "The Zebra Ball - Stars for the Stripes" Promoted Carcinoid Cancer Wearing mostly black and white or Valentine red attire accessorized by zebra-striped awareness pins and bracelets, 150 guests gathered at The Peninsula Chicago to promote awareness of a rare form of cancer: carcinoid cancer.
In its third year, to date the event has raised close to $100,000 to support the mission of The Carcinoid Cancer Foundation, Inc. Read more and view pictures from this special event
For the fourth concecutive year CCF exhibits at the ASCO annual conference in Orlando, FL May 31 - June 3, 2009 to to fulfill one of our and NCI's most important missions; Educate the medical professionals.
More than 500 medical professionals visited the CCF booth in 2008.
NANETS (North American NeuroEndocrine Tumor Society) was established in September 2006. The purpose of this professional organization is to improve neuroendocrine tumor (NET) disease management through increased research and educational opportunities
Carcinoid & Neuroendocrine Tumor Society is an association of patients, caregivers and physicians, promoting better understanding of carcinoid and neuroendocrine cancer, a relatively rare disease which is poorly understood and is often misdiagnosed
About CNETS of Singapore.:
The association was formally registered on 9 April 2009 (ROS Number 2039/2009). The founders of the association are Dr. Paul Ho, Lam Wei Choong, and William Claxton. Founding members include local and foreign patients, and many prominent Carcinoid NETs specialist physicians in Singapore.
The vision for establishing a network of regional support groups to help patients, caregivers and physicians involved with carcinoid and neuroendocrine tumors was first articulated by Maureen Coleman, co-founder and President of the Carcinoid-NeuroEndocrine Tumour Society Canada, and Sandi Barkan, NAAPNET President, at an international conference on Carcinoid and Neuroendocrine Tumors held in Norfolk Virginia in September 2007. Their vision was dubbed 'CNETS without borders'. CNETS Singapore was born of that vision, and works actively to coordinate with other regional support groups
Contacts for Carcinoid-NeuroEndocrine Tumour Society Canada and other support groups can be found on our resources page
For Medical Professionals
New Peer Review Articles
Raymond E, Faivre S, Hammel P, Ruszniewski P.
Department of Medical Oncology and Gastroenterology,
Beaujon University Hospital, Clichy, France, eric.raymond@bjn.aphp.fr
Targeted Oncology (2009) 4:253-254
ABSTRACT: Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.
PMID: 19911111 [PubMed – as supplied by publisher]
Ursula Plöckingera Björn Gustafssonb Diana Ivanc Waldemar Szpakd
Joseph Davare and all other Mallorca Consensus Conference participants
a Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany;
b Medisinsk avd Gastroseksjon, St Olavs Hospital HF, Trondheim, Norway;
c Endocrinology and Diabetology, Klinikum der Philipps-Universität, Marburg, Germany;
d Westville Hospital, Amanzimototi, Mayville, South Africa; e Department of Cardiology, Royal Free Hospital, London, UK
Neuroendocrinology 2009; 90:190-193
INTRODUCTION: Carcinoid heart disease is observed in 3–4% of all patients with a neuroendocrine tumor and in 40–50% of those with a carcinoid syndrome [1, 2]. Details on well differentiated neuroendocrine jejunal-ileal tumors have already been discussed in the ENETS Consensus Guidelines and the reader is referred to these Guidelines [3]. Here technical questions and quality management for the diagnosis and follow-up of carcinoid heart disease will be discussed. Involvement of the tricuspid leaflets grade 2–3 occurs in 90%, a stenosis of the pulmonary leaflets in 50%, while regurgitation is seen in 81% of the patients during the course of the disease [4, 5] . Carcinoid heart disease is a relatively late manifestation of neuroendocrine tumors; however, it has an important impact on the prognosis of these patients. Thus, early diagnosis and treatment is mandatory in each patient with a carcinoid syndrome. Echocardiography is the gold standard for detection of carcinoid heart disease. This article will concentrate on technical details for echocardiography. The information provided should help those not experienced with this disease to diagnose carcinoid heart disease and provide high-quality information of echocardiographic investigations. The information provided by echocardiography will be the basis for clinical decisions and may well influence the prognosis and outcome of the patient.
PMID: 19713710 [PubMed – as supplied by publisher]
Catharina M. Korse, Babs G. Taal, Cornelis A. de Groot, Robert H. Bakker, and Johannes M.G. Bonfrer
Journal Clinical Oncology 27:4293-4299
CONCLUSION: N-terminal pro-brain natriuretic peptide (NT-proBNP) and chromogranin-A (CgA) are very important markers in the diagnosis of CHD in patients with NET. Furthermore, patients with elevated NT-proBNP in addition to elevated CgA levels showed worse overall survival than patients with elevated CgA alone.
PMID: 19667278 [Pubmed – as supplied by publisher]
BACKGROUND: Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow-up are lacking. AIM: To present long-terms results with octreotide LAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome.
METHODS: A total of 108 patients with metastatic midgut neuroendocrine tumours were included in this 8-year study. Clinical evaluation was based on a symptom score. Radiological assessment was based on RECIST (Response Evaluation Criteria In Solid Tumours) criteria.
RESULTS: Of the 108 patients, 24% had a sustained symptomatic response. In the remaining patients, loss of symptomatic response with the initial dose was noted within 3-60 months. In 17% of them, symptoms were controlled by just an increase of octreotide LAR dose, whilst the other patients required additional treatment. Overall, in 45.3% of patients, symptoms were well controlled during the study period with only octreotide LAR, and no additional treatment was required. No significant adverse effects were noted.
CONCLUSIONS: Octreotide LAR treatment provides a sustained symptomatic response in about half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described. PMID: 19573169 [PubMed - in process]
Vinik AI, Silva MP, Woltering G, Go VL, Warner R, Caplin M.
Eastern Virginia Medical School, Strelitz Diabetes Research Center, Norfolk, VA 23510, USA. vinikai@evms.edu
ABSTRACT: In this review, we focus on the use of biochemical markers for the diagnosis of neuroendocrine tumors and exclusion of conditions that masquerade as neuroendocrine tumors. In addition, we outline the use of biochemical markers for follow-up, response to intervention, and determination of prognosis. Previous publications have focused only on markers specific to certain tumor types, but the uniqueness of this chapter is that it presents a new approach ranging from biochemical markers that relate to symptoms to the use of markers that facilitate decision making with regard to optimizing the choices of therapy from the complex arrays of intervention, The sequence of presentation in this chapter is first to provide the usual view, that is, biochemical markers of each tumor type and thereafter the diagnosis of the underlying condition or exclusion thereof and finally the algorithm for their use from the clinical presentation to the suspected diagnosis and the biochemical markers to monitor progression and therapeutic choice. There is also a specific description of the properties of the most important biochemical markers and 2 complications, bone metastasis and carcinoid heart disease, from the biochemical point of view.
PMID: 19855234 [PubMed - in process]
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold, Thomas Gress, and Rudolf Arnold
Journal of Clinical Oncology. 2009 Oct 1;27(28):4656-63.
Conclusion: Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
"In recent years, a growing body of evidence has suggested that SandostatinLAR provides antitumor effects, but these are the first data to confirm this effect from a well-designed, prospective, placebo-controlled study," said David Epstein,President & CEO of Novartis Oncology.
EAST HANOVER, N.J., Jan. 13 /PRNewswire/ -- Sandostatin LAR(R) Depot (octreotide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuroendocrine tumors (NETs) of the midgut,according to interim data presented today at the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology.
- Data show significant 66% reduction in risk of disease progression versus placebo
- Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on
placebo
- Results support Sandostatin LAR as first treatment after surgery in certain patients with newly diagnosed neuroendocrine tumors (NETs)
ABSTRACT:A National Cancer Institute summit meeting on gastroenteropancreatic neuroendocrine and carcinoid tumors was held in September 2007 to present the currently accepted standards of care for patients with these tumors and to identify areas requiring investigation and development. These tumors are clinically and pathologically heterogeneous, present commonly with obscure symptoms that lead to delays in diagnosis of years, and have an incidence in the United States of 2.5 to 5 cases per 100 000. The 5-year survival rates range between 15% and 95%, depending on the site and extent of disease. This report delineates the main conclusions of the meeting, including the best practice diagnosis and treatment strategies for gastropancreatic neuroendocrine tumors, and the identification of clinical and scientific areas that are most in need of attention.The most pressing needs were public and physician education,identification of molecular markers for early diagnosis and therapeutic monitoring, improved imaging modalities and molecular
prognostication, development of a standardized pathological classification system, and creation of regional centers of expertise
with tumor and laboratory data banks. In addition, adequately validated neuroendocrine tumor models and cell lines should be established to investigate the molecular mechanisms involved in the control of their growth and secretion, and to facilitate the development of specific therapies that should be examined in well-designed multicenter studies of defined patient groups.
CONCLUSIONS.: In this open study of 34 patients, the results demonstrated that radioembolization with (90)Y resin microspheres can achieve relatively long-term responses in some patients with nonresectable NETLMs.
CONCLUSION: Radioembolization with 90Y-Microspheres to the whole liver, or lobe with single or multiple fractions are safe and produce high response rates, even with extensive tumor replacement of normal liver and/or heavy pretreatment. The acute and delayed toxicity was very low without a treatment related grade 4 acute event or radiation induced liver disease in this modest-sized cohort. The significant objective response suggests that further investigation of this approach is warranted
CONCLUSIONS: Current plasma octreotide values are significantly lower than previously reported for 30-, 60-, and 120-mg/mo LAR doses. Serial plasma octreotide value measurements should be used to determine if increasing symptoms or tumor growth are associated with suboptimal drug dosing.
Webcasts fromNANETS Conference 2008, Southampton Bermuda "New Horizons in NET Management" are now available from their website. ABOUT NANETS:NANETS ( North American NeuroEndocrine Tumor Society) was established in September 2006. The purpose of this professional organization is to improve neuroendocrine tumor (NET) disease management through increased research and educational opportunities.
CONCLUSION: Pancreatoduodenectomy for adenocarcinoma in the head of pancreas can provide long-term survival in a subset of patients, particularly in the absence of lymph node metastasis. One of 8 patients can achieve 10-year survival with a potential for cure.
PMID: 18376190 [PubMed - indexed for MEDLINE]
Javier G. Castillo, Farzan Filsoufi, Parwis B. Rahmanian, Anelechi Anyanwu, Jerome S. Zacks, Richard R.P. Warner, David H. Adam Journal of the American College of Cardiology
Volume 51, Issue 15, 15 April 2008, Pages 1507-1509
Pages 1507-1509 Full Text
Massimo Rugge1,4,5, Matteo Fassan1, Roberto Clemente4, Giovanna Rizzardi2, Luciano Giacomelli5, Gianmaria Pennelli1,4, Claudia Mescoli1, Daniela Segat3 and Federico Rea2
Clinical Cancer Research 14, 149-154, January 1, 2008. doi: 10.1158/1078-0432.CCR-07-1631
Requests for reprints: Massimo Rugge, Cattedra di Anatomia Patologica, Università degli Studi di Padova, Istituto Oncologico Veneto-IRCCS, Via Aristide Gabelli, 61, 35121 Padua, Italy. Phone: 39-0498-272-252; E-mail: massimo.rugge@unipd.it
.
Purpose: The histologic distinction between low-grade typical and intermediate-grade atypical bronchopulmonary carcinoids basically lies on cellular differentiation, mitotic activity, and presence of "neoplastic" necrosis; at single patient level, however, none of these features enables a reliable prediction of the clinicopathologic outcome.
Conclusions: Mib1 and Bcl2 significantly discriminate between recurrent versus nonrecurrent tumors, producing a biologically plausible, diagnostically suitable immunohistochemical pattern.
What is Cell culture drug resistance testing (CCDRT) ?
Also known as "chemotherapy sensitivity and resistance assays" or ("CSRAs")
This journal
describes the CCDRT and its use to identify the best forms of chemotherapy for cancer patients on an individual basis.
J Surg Oncol. 2007 Oct 1;96(5):397-403 Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR.
Department of Surgery, Division of General Surgery, The Mount Sinai School of Medicine, New York, New York 10029-6574, USA. scott.nguyen@mountsinai.org CONCLUSION: Patients with malignant pancreatic neuroendocrine tumors commonly present with advanced disease. Although, curative resection is not frequent, survival benefit may be obtainable with aggressive surgical management even in the face of metastatic disease.
J Vasc Interv Radiol. 2007 Jul;18(7):847-55
Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO.
Division of Interventional Radiology, University of Pennsylvania, 1 Silverstein, Philadelphia, PA 19104, USA. CONCLUSIONS: Chemoembolization was not associated with a higher degree of toxicity than bland embolization. Chemoembolization demonstrated trends toward improvement in TTP, symptom control, and survival. Based on these results, a multicenter prospective randomized trial is warranted
Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A,
Rothmund M
Department of Surgery, Philipps-University Marburg, Marburg, Germany. fendrich@med.uni-marburg.de
Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3.
OBJECTIVE: To evaluate the outcome of reoperations in patients with duodenopancreatic neuroendocrine tumors (PETs) in a tertiary referral center.
CONCLUSIONS: We show that an aggressive surgical approach leads to long-term survival in patients with malignant PETs. Although long-term cure can only be achieved in a proportion of patients with malignant PETs, significant long-term palliation can be achieved.
Journal of Surgical Oncology
Volume 94, Issue 5, Date: 1 October 2006, Pages: 396-402
John C. Byrn, Ju-Lin Wang, Celia M. Divino, Scott Q. Nguyen, Richard R.P. Warner
Background and Objectives: Goblet cell carcinoid, a rare tumor of intermediate malignant potential, is known to account for a significant minority of appendiceal neoplasms. Sixteen new cases of gastrointestinal goblet cell carcinoid were reviewed to describe their presentation, treatment, and outcome.
Conclusions: Goblet cell carcinoid is a rare malignant tumor largely affecting the appendix. In patients presenting with appendicitis, our series does not support the recommendation of right hemicolectomy based on pathologic diagnosis alone and surgical intervention must be customized to the individual patient.
Liesbeth M Veenendaal1, Inne HM Borel Rinkes1, Cornelis JM Lips2 and Richard van Hillegersberg*1 Netherlands.
Published: 26 June 2006 World Journal of Surgical Oncology 2006, 4:35
Review Abstract : Background: Neuroendocrine tumours frequently metastasize to the liver. Although generally slowly progressing, hepatic metastases are the major cause of carcinoid syndrome and ultimately lead to liver dysfunction, cardiac insufficiency and finally death.
Conclusions: Treatment for patients with neuroendocrine hepatic metastases must be tailored for each individual patient. When local ablative therapies are used early in the course of the disease, the occurrence of carcinoid syndrome with end stage hepatic disease can be postponed or prevented.
Last Modified:
[an error occurred while processing this directive]
(6/14/10) Novartis Oncology to Honer Monica Warner with Adocacy Award
(11/23/09) Carcinoid Cancer Foundation Appoints New CEO
The Lois Merrill Foundation
For the fourth concecutive year CCF exhibits at the ASCO annual conference in Orlando, FL May 31 - June 3, 2009 to to fulfill one of our and NCI's most important missions; Educate the medical professionals. 
